This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Neurogen Corporation. Active years: 1997-2006.
Location History:
- Guilford, CT (US) (1997)
- New York, NY (US) (2004 - 2006)
Company Filing History:
Years Active: 1997-2006
Title: John Tallman: Innovator in GABA-Modulatory Compounds
Introduction
John Tallman is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmacology, particularly in the development of methods for screening GABA-modulatory compounds. With a total of 4 patents, Tallman's work focuses on enhancing cognitive and therapeutic properties of various compounds.
Latest Patents
Tallman's latest patents include innovative methods for screening GABA-modulatory compounds for specified pharmacological activities. These methods are designed to assay compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. The processes involve determining the in vitro efficacy and EC of the compounds at defined series of cloned GABA subtype receptors, which are composed of specific variants of α, β, and γ subunits. This approach allows for the development of an activity profile for each compound. Additionally, the binding affinities of the compounds at GABA receptors may also be assessed. As a further step, the in vivo effects of the compounds can be tested in animal models.
Career Highlights
Tallman is currently associated with Neurogen Corporation, where he continues to advance his research and innovations. His work has been instrumental in the exploration of cognitive and therapeutic enhancements through GABA-modulatory compounds.
Collaborations
Some of his notable coworkers include Kenneth Shaw and Dorothy Gallager, who have collaborated with him on various projects within the field.
Conclusion
John Tallman's contributions to the field of pharmacology through his innovative methods for screening GABA-modulatory compounds highlight his role as a significant inventor. His work continues to pave the way for advancements in cognitive and therapeutic applications.